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Involvement of thromboxane A2, leukotrienes and free radicals in
puromycin nephrosis in rats. Thromboxane A2 (TXA2), leukotrienes
(LTs) and free radicals are considered to be possible mediators in the
induction of glomerular injury and proteinuria. In this study, we
examined the involvement of these three mediators and the protective
effect of simultaneous inhibition of all three in puromycin aminonucle-
oside (PAN) nephrosis in rats. A single intraperitoneal injection of PAN
(100 mg/kg) induced massive proteinuria and enhanced production of
TXA2 and LTs from arachidonic acid in renal cortical slices and renal
glomeruli, and increased malondialdehyde levels in plasma, urine and
renal cortex. Oral administration of CV-6504(HCI) (3 to 20 mg/kg/day,
for I to 2 weeks), a novel treble inhibitor of TXA2 synthetase,
5-lipoxygenase and lipid peroxidation, dose-dependently attenuated
PAN-induced proteinuria and the increases in these three mediators.
Any single specific inhibitor (CV-4l51, a TXA2 synthetase inhibitor;
AA-861, a 5-lipoxygenase inhibitor; or CV-361 I, a radical scavenger) or
a combination of two inhibitors showed no or only a slight antiprotein-
uric effect, but the combination of all three inhibitors significantly
reduced PAN-induced proteinuria. These results suggest that, these
three mediators may be involved in the pathogenesis of PAN nephrosis
and that CV-6504(HCI), which can simultaneously inhibit all three, may
be a useful therapeutic agent for nephrosis.
Several recent studies have indicated that reactive oxygen
metabolites [1—51, thromboxane A2 (TXA2) [6, 7] and leuko-
trienes (LTs) [8—111 may play important roles in the pathophys-
iology of renal glomerular diseases. A variety of inhibitors of
these mediators are known to protect against glomerular injury
and proteinuria in various forms of experimental nephropathy.
A single i.p. injection of puromycin aminonucleoside (PAN)
in rats causes marked proteinuria and a glomerular morphologic
abnormality (epithelial cell injury) that are similar to minimal
change nephrotic syndrome in humans [12]. Recently, Dia-
mond, Bonventre and Karnovsky [4] postulated that the gb-
merular injury associated with PAN treatment is mediated by
generation of oxygen free radicals. In addition to oxygen free
radicals, the metabolites of arachidonic acid such as TXA2 and
LTs may be involved in the pathogenesis of PAN nephrosis,
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because oxygen free radicals are known to stimulate the pro-
duction of TXA2 and prostaglandin E2 in cultured rat mesangial
cells [13], and because PAN treatment also activates phospho-
lipase which digests membrane phospholipids causing the re-
lease of arachidonic acid (AA; a precursor of TXA2 and LTs)
[14]. Enhanced synthesis of TXA2 and prostaglandins has been
reported to influence renal function and hemodynamics [6,
15—20]. However, the nature of renal production of TXA2 and
LTs and renal lipid peroxidation has not yet been examined at
the same time in PAN-induced nephrosis.
CV-6504(HCI), 2,3 ,5-trimethyl-6-(3-pyridylmethyl)- 1,4-ben-
zoquinone hydrochloride, has three different pharmacologic
actions: it inhibits TXA2 synthetase and 5-lipoxygenase, and
scavenges free radicals [21]. If all three of the above-mentioned
mediators are involved in PAN-induced nephrosis, an agent
such as CV-6504(HC1), which can simultaneously inhibit all
three, should be much more effective in the treatment of the
disease than a pure inhibitor of one individual mediator.
Therefore, the aim of the present study is to examine the
possible involvement of TXA2, LTs and lipid peroxidation in
PAN-induced nephrosis and the effect of CV-6504(HCI) on the
proteinuria.
Methods
Experimental design
Adult male Wistar rats that weighed 120 to 130 g (5 weeks old)
and had free access to water and standard rat chow were used
in these experiments. Nephrotic syndrome was induced by a
single i.p. injection of PAN at a dose of 100 mg/kg body weight
[22].
Experiment I
To investigate the time course of changes in blood, urinary
and renal tissue parameters, blood, urine and renal tissue were
obtained day 1 (N 5), 3 (N 5), 7 (N = 5) and 14 (N = 7) after
PAN injection. Blood was collected from the abdominal aorta
under pentobarbital anesthesia. Plasma samples were subjected
to procedures for the measurement of MDA, BUN, total
protein, albumin, creatinine and total cholesterol. The kidneys
were removed and subjected to a biosynthetic study on renal
TXA2, PGI2, LTs and MDA as described later.
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Experiment 2
CV-6504(HC1) at doses of 3 (N = 11), 10 (N = 21) and 20 (N
= 11) mg/kg was given orally once a day for 14 days. The first
dose of CV-6504(HC1) was given one hour prior to the PAN
injection. Control rats (N = 10) were given only vehicle (5%
gum arabic solution). Urine was collected on days 7 and 14 after
PAN injection, and urinary total protein and albumin were
measured. On day 14, the effects of CV-6504(HCI) (10 mg/kg)
on the changes in various blood and urinary parameters induced
by PAN injection, the production of TXA2 and LTs and the
production of MDA in renal cortical slices were analyzed as
described later. The kidneys from rats receiving CV-6504(HC1)
at 10 mg/kg (p.o.) were also examined histologically day 14 after
PAN injection.
Experiment 3
CV-6504(HCI) was administered for 14 days at 10 mg/kg/day
(p.o., N = 8) beginning one day after PAN injection. Urine was
collected on days 8 and 15 after PAN injection.
Experiment 4
To investigate the in vitro effect of CV-6504(HCI) on the
production of TXA2, LTs and MDA, CV-6504(HC1) was added
to the incubation medium of fresh renal cortical slices from
control rats day 14 after PAN injection. Further, to estimate the
ex vivo effect of a single dose of CV-6504(HCI), CV-4151,
AA-861 or CV-361 1 on the production of TXA2, LTs or MDA,
each drug was administered to control rats day 14 after PAN
injection, and one hour later the kidneys were isolated. The
production of TXA2, LTs or MDA was then analyzed in renal
cortical slices or renal glomeruli as described later.
Experiment 5
The effects of the combined administration of CV-4 151 (a
TXA2 synthetase inhibitor [23]), AA-86l (a 5-lipoxygenase
inhibitor [24]) and CV-361 I (a radical scavenger [25]) on the
proteinuria in PAN-induced nephrosis were examined. Nine
groups were used: (a) normal rats without PAN injection (N =
7), (b) vehicle (N = 7), (c) CV-4151 10 mg/kg, p.o. (N = 7), (d)
CV-3611 50mg/kg, p.o. (N = 7), (e) AA-861 300 mg/kg, p.o. (N
= 7), (f) CV-4151 + CV-3611 (N = 7), (g)AA-861 + CV-3611 (N
= 7), (h) AA-861 + CV-4l51 (N =7) and (i) AA-861 + CV-4l51
+ CV-361 1 (N = 7). In groups (b) through (i) the first dose of
vehicle or drug was administered one hour prior to PAN
injection. At the doses of CV-4151, AA-861 and CV-3611 used
in this experiment, significant inhibitory effects on the produc-
tion of TXA2, LTs and MDA in renal cortical slices, respec-
tively, were shown in Experiment 4.
Miscellaneous measurements
Urinary protein was measured using a A/G-B test® (Wako,
Japan) based on Biuret reaction [26], and urinary and plasma
albumin were measured using an Albumin-B test® with brom-
cresol green [27] (Wako). Plasma cholesterol, BUN and plasma
creatinine were measured using a cholesterol Etest® (a modi-
fied cholesterol oxidase method by Richmond et al [28, 29]) and
a Creatinine test® (Wako) based on the Jaffe reaction [30],
respectively. MDA in plasma, urine, renal cortex and the
incubation medium of renal cortical slices was measured using
a Lipoperoxide test® (Wako) based on thiobarbituric acid
(TBA) method [31]. To measure plasma and urinary excretion
of I 1-dehydro-TXB2 and LTB4, urine and plasma were ex-
tracted with 4 volumes of ethyl acetate in the tubes including
indomethacin (10—6 M) for ll-dehydro-TXB2 [32] and cold
methanol for LTB4 [33]. LTB4 and 11-dehydro-TXB2 were
measured by RIA using kits (Amersham, Arlington Heights,
Illinois, USA).
Preparation and incubation of renal cortical slices or renal
glomeruli, and measurement of TXA2, LTs and MDA
The biosynthesis of renal TXA2, PGI2 and LTs and the
production of renal MDA were examined as follows: kidneys
were perfused with ice-cold Krebs-Henseleit solution (20 ml) to
remove blood. The renal cortex of the right kidney was re-
moved quickly and cut into 0.3 mm-thick slices using a tissue
chopper (McLwein) or glomeruli were prepared using three
consecutive sieves (mesh size 120, 133 and 35 m) according to
the method of Fujiwara et al [34]. Purity of the glomeruli was
assessed by light microscopy. Preparations were found to
contain more than 95% glomeruli. The slices (about 10 mg) or
glomeruli (about 4000) were suspended in 2 ml of Krebs-
Henseleit solution (gassed with 95% 02-5% C02). Arachidonic
acid (AA) was added at a final concentration of 20 M.
Incubation with or without AA was carried out at 37°C for 30
minutes under continuous agitation (80 cycles/mm) and was
terminated by centrifugation at 1500 x g for five minutes. The
supernatant (0.3 ml) was extracted with 1.2 ml cold methanol to
measure LTs, and an aliquot of the supernatant was immedi-
ately frozen to measure TXB2 (the stable metabolite of TXA2)
and 6-keto-PGF1,, (the stable metabolite of PGI2). LTs were
measured by radioimmunoassay (RIA) using kits (Amersham)
sensitive to LTC4, LTD4 and LTE4. TXB2 and 6-keto-PGF1
were also measured by RIA using TXB2 or 6-keto-PGF1,
antiserum as described before [23, 35j. Cross reactivity of TXB2
antiserum with other prostaglandins was less than 0.1% for
PGEI and PGE2, 0.6% for PGF2,, 0.1% for 6-keto-PGF1,, and
1.1% for PGD2. That of 6-keto-PGF1, antiserum was less than
0.1% for PGA2, PGD2 and TXB2, 1.8% for PGE1, 1.3% for
PGE2, 4.5% for PGF2, 0.4% for 6, 15-diketo-PGF1 and 0.3%
for 6, 15-diketo- 13, 14-dihydro-PGF1,.
To assay the production of MDA, the residual slices (40 mg)
were incubated in 0.5 ml of phosphate-buffered saline at 37°C
for 45 minutes, and then the level of MDA in the incubation
medium was measured using a Lipoperoxide test as described
above. To measure renal content of MDA, the left kidneys were
homogenized in 9 volume of phosphate buffered saline, and the
level of MDA in the homogenates was measured as described
above. The amount of protein in the slices or homogenates was
determined by the method of Lowry et a! using BSA as the
standard [36].
Histological examination
For light microscopic examination, the kidneys were fixed in
10% buffered formalin and embedded in paraffin. Sections 4 sm
thick were stained with hematoxylin-eosin and periodic acid
Schiff (PAS) and were then examined under a Nikon Microphot
light microscope. A portion of the renal tissue was rapidly
removed and fixed in ice-cold 3% glutaraldehyde solution. The
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Table 1. Time course of the changes in the concentration of BUN, plasma creatinine, plasma albumin and plasma cholesterol after PAN
injection in Experiment 1
Days after PAN
injection 1 3 7 14
Number of animals 5 5 5 7
BUN Normal 15.4 1.20 14.8 0.8 15.3 0.9 16.0 0.8
mg/dl PAN 21.8 O.99a 21.9 0.9 94.2 5.8 21.5 l.o
1Cr
mg/dl
Normal
PAN
0.400 0.006
0,410 0.002
0.405 0.002
0.402 0.001
0.395 0.011
0.442 0.0O2'
0.406 0.003
0.414 0.009
P,
gidi
Normal
PAN
3.37 0.15
3.16 0.09
3.19 0.16
3.42 0.09
3.43 0.07
2.00 002b
3.59 0.05
3.19 0.12a
1cho1
mg/dl
Normal
PAN
60.9 2.5
80.3 8.5
63.4 3.8
88.4 4.Oa
54.6 3.8
330.4 15,8c
65.9 4.1
166.3 153b
Abbreviations are: PAN, puromycin aminonucleoside, 100 mg/kg, i.p.; Cr' plasma creatinine concentration; plasma albumin concentra-
tion; thoI' plasma cholesterol concentration.a P < 0.05, b P < 0.01 and C P < 0.001 vs. normal rat (Student's t-test)
specimens were post-fixed in 1% osmic acid, dehydrated
through a graded ethanol series, and then embedded in epoxy
resin. Ultrathin sections were cut and stained with uranyl
acetate and lead citrate, and examined under a JEM 1200EX
(Tokyo, Japan) electron microscope. The criteria scoring was
as follows.
PAS positive droplet. Score 1, a few deposits in a small
number of glomeruli; score 2, a few deposits in a large number
of glomeruli; score 3, extensive deposits in a small number of
glomeruli; and score 4, extensive deposits in a large number of
glomeruli.
Hyalin cast. Score 1, seen rarely (less than ten tubules); score
2, seen in a small number of tubules; score 3, seen in many
tubules; and score 4, seen in over half the tubules.
Dilatation and basophilic alteration and atrophy. Score 1,
seen rarely; score 2, seen sometimes; and score 3, seen dif-
fusely.
Cell infiltration (extensively monocytes, neutrophils and lym-
phocytes were rare). Score 1, scattered; and score 2, diffuse or
crowded.
Fibrosis. Score 1, focal infiltration of fibroblasts, and score 2,
diffuse infiltration of fibroblasts.
In all cases, score of 0 represents no changes.
Statistical analysis
Normally distributed data were expressed as mean SE. A
one-way analysis of variance and Dunnett's test were used for
multiple comparisons, and Student's t-test was used for the
comparison of two groups where data were confirmed to be
normally distributed. In the case of histological examination,
differences among groups were compared using the non-para-
metric Mann-Whitney U test. A probability value less than 0.05
was regarded as significant.
Agents
CV-6504(HC1), CV-4 151 [(E)-7-Phenyl-7-(3-pyridyl)-6-hep-
tenoic acid], AA-861 [2-( 12-Hydroxydodeca-5, 10-dinyl)-3, 5,
6-trimethyl-1, 4-benzoquinonej and CV-36l 1 (2-0-Octadecy-
lascorbic acid) were synthesized in the Chemistry Research
Laboratories of Takeda Chemical Industries, Ltd. All agents
except the kits from Wako and Amersham were purchased from
Sigma Chemical Co. (St. Louis, Missouri, USA).
Results
Time course of the changes in various parameters in plasma,
urine and renal cortex (Experiment 1)
The time course of the changes in various parameters in
plasma, urine and renal cortical slices is shown in Table 1 and
Figure 1. The BUN level was slightly but significantly increased
day I after PAN injection, and the plasma cholesterol level was
increased on day 3 (Table 1). However, the urinary excretion of
protein was not significantly increased on day 1 or day 3.
Massive proteinuria was observed on day 7 (Fig. 1 A and B)
accompanied by marked increases in the level of plasma cho-
lesterol, BUN (Table 1), plasma MDA (Fig. 1C) and plasma
creatinine concentration and a decrease in the plasma albumin
concentration (Table 1). The content of MDA in the renal
cortex was not increased on day 1 or day 3, while it was
significantly increased on day 7 (0.98 0.05 nmollmg protein;
Fig. lD). However, day 7 after PAN injection the production of
MDA by incubated slices was not enhanced in the renal cortical
slices from the PAN treated rats (0.63 0.07 nmol/mg protein)
in comparison with that in those from normal rats (0.90 0.05
nmol/mg protein). Urinary excretion of MDA was increased on
day 1 (9.4 1.9 vs. 2.1 0.4 nmol!lOO g/24 hr in the normal
rats), day 7 (16.4 0.8 vs. 4.3 1.4 nmolIlOO g124 hr in the
normal rats) and day 14 (18.6 1.1 vs. 4.2 0.2 nmolllO0 g124
hr in the normal rats; Fig. 1C). In contrast, the production of
TXB2, 6-keto-PGF1 and LTs induced by AA (20 /LM) in the
renal cortical slices was significantly increased starting day 1
and peaked on day 7 after PAN injection: day 1, 0.08 0.03,
0.24 0.06 and 16.9 3.4 nglmg protein for TXB2, 6-keto-
PGFI,, and LTs, respectively; day 3, 0.08 0.01, 0.11 0.02
and 21.2 2.5 ng/mg protein for TXB2, 6-keto-PGF1, and LTs,
respectively; day 7, 0.27 0.07, 0.34 0.08 and 23.7 3.2
ng/mg protein for TXB2, 6-keto-PGF1a and LTs, respectively
(Fig. 1 E and F). In the normal rats, these values were 0.01 to
0.04 nglmg protein/30 mm for TXB2, 0.07 to 0.12 ng/mg pro-
tein/30 mm for 6-keto-PGF1, and 0 to 0.18 nglmg protein/30 mm
for LTs. The basal values of TXA2 and LTs in the absence of
AA were slightly higher in PAN control rats (TXA2; 0.006
0.004 nglmg protl30 mm, LTs; 0.015 0.004 ng/mg prot/30 mm;
summation of values on 1, 3, 7 and 14 days after PAN injection,
N = 22) than in normal rats (TXA2; 0.002 0.001 nglmg protl30
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mm, LTs; 0.006 0.004 ng/mg prot/30 mm, N = 22), but this
difference was not significant.
Antiproteinuric action of CV-6504(HC1): Experiments 2 and 3
The quantity of urinary total protein and albumin in the
normal rat was 16.6 4.5 and 2.0 0.7 mg/100 g/24 hr on day
7, respectively, and 20.3 2.3 and 0.9 0.3 mg/l00 g/24 hr on
day 14, respectively. In rats given PAN, urinary total protein
and albumin excretion increased markedly, and reached a peak
between days 7 and 14 after PAN injection (urinary excretion of
total protein: 128.6 11.3 and 103.6 14.2 mg/100 g/24 hr on
day 7 and day 14, respectively; urinary excretion of albumin:
77.6 9.0 and 64.3 10.2 mg/l00 g/24 hr on days 7 and 14,
respectively). CV-6504(HC1) at doses of more than 3 mg/kg
(p.o.) suppressed the proteinuria. The effects at 10 and 20 mg/kg
were remarkable (Fig. 2; urinary excretion of total protein:
CV-6504(HC1) 3 mg/kg/day; 87.8 13.5 and 47.5 10.7, 10
mglkglday; 26.4 4.1 and 28.5 4.8, 20 mg/kg/day; 21.8 5.1
and 26.3 7.8 mgIlOO g124 hr on days 7 and 14, respectively;
urinary excretion of albumin: CV-6504(HCI) 3 mg/kg/day; 52.6
9.1 and 26.8 7.3, 10 mg/kg/day; 10.5 2.9 and 9.5 2.9,
20mg/kg/day; 3.4 1.1 and 8.8 5.9 mgIlOO g/24 hr on days 7
and 14, respectively). CV-6504(HCI) did not affect urine volume
(Table 2). In the case of Experiment 3 (the first administration
of CV-6504(HC1) was 1 day after PAN injection), this drug also
attenuated the proteinuria on day 7 and day 14 (albumin
excretion: on day 7, 64.4 10.0 for control; N = 8; and 5.9
3.5 for CV-6504(HC1); N = 8; P < 0.01 vs. PAN-control; on day
14, 53.0 8.2 for control; N = 8; and 5.1 2.1 for CV-
6504(HCI); N = 8; P < 0.01 vs. PAN-control).
Histological findings in the kidney: Experiment 2
The weight of the kidney tended to increase in the group
receiving PAN alone: normal rats, 0.82 0.08 g; PAN-control
rats, 1.05 0.28 g; CV-6504(HCI) (10 mglkglday)-treatëd rats,
0.96 0.14 g (Table 2).
Light microscopy. On day 14 of the experiment, infiltration of
inflammatory cells into the glomeruli was not observeçj, but,
deposits of PAS-positive materials were observed in the gb-
meruli of the rats given PAN alone. The renal tubules also
showed prominent changes such as hyalin cast formation,
dilatation, bäsophilic alteration and atrophy. The infiltration of
a few inflammatory cells into the interstitial cells and the
proliferation of fibroblasts in the interstitial cells were observed
in the control rats receiving PAN alone. The occurrence of
hyalin casts and cell infiltration was significantly reduced in the
CV-6504(HCI) treated group (Table 3).
Electron microscopy. Electron microscopic examination of
the glomeruli in rats treated with PAN revealed a definite
abnormality in the epithelial cells. The foot processes of the
epithelial cells were replaced by an expanse of flattened epithe-
hal cytoplasm in the PAN-treated rat (Fig. 3A). In addition,
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Fig. 1. The time course of the changes in urinary protein,
plasma MDA concentration, urinary MDA, renal MDA
content and the production of renal TXA2, 6-keto-PGF1 and
LTs in PAN treated rats (Experiment 1). The closed circles
and triangles show the values for PAN treated rats and the
open circles and triangles show the values for normal rats. (A)
Urinary total protein, (B) urinary albumin, (C) plasma MDA(•, 0) and urinary MDA (A, ), (D) renal MDA ëontent, (E)
TXB2 (S, 0) and 6-keto-PGF1,, (A, L) produced from
arachidonic acid in renal cortical slices, (F) LTs produced
from arachidonic acid in renal cortical slices. The number of
animals is 5 (day 1 — day 7) or 7 (day 14). < 0.05, <0.01, 'P < 0.001 vs. normal rats (Student's (-test).
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Fig. 2. The effect of CV-6504(HC1) on puromycin aminonucleoside
(PAN)-jnduced proteinuria in Experiment 2. Abbreviations are: a,
saline, N = 10; b, PAN, N = 15; c, CV-6504(HCI) 3 mg/kg, p.o., N =
11; d, CV-6504(HC1) 10 mglkg, p.o., N = 21;e, CV-6504(HCI) 20 mglkg,
p.o., N = 11. All groups received a single intraperitoneal injection of
PAN at a dose of 100 mg/kg body weight, except for the saline group
which received a single intraperitoneal injection of saline. CV-
6504(HCI) was administered 1 hour prior to PAN injection, The data
shown are the means SE. *R < 0.05, < 0.01 vs. PAN control
(Dunnett's test)
vacuoles and granular material were observed within the cyto-
plasm of the epithelial cell. The extent and severity of lesions in
the epithelial cells in the rats treated with CV-6504(HCI) were
significantly less than that in the control rat receiving PAN
along (Fig. 3B). No endocapillary cell proliferation, mesangial
abnormalities or sclerosis was observed in either group.
Body weight and plasma levels of albumin, cholesterol and
BUN: Experiment 2
The body weight of PAN-treated rats was significantly lower
than that of normal rats day 14 after PAN injection. CV-
6504(HC1) inhibited this reduction in body weight (Table 2). The
level of plasma albumin in the PAN group (3.11 0.09 g/dl) was
significantly lower than that in the normal rats (3.87 0.09
gldl), and the levels of plasma cholesterol (187.5 21.4 mg/dl)
and BUN (26.6 2.2 mg/dl) in these rats were higher than those
in normal rats (76.6 4.5 mg/dl for cholesterol and 16.8 1.5
mg/dl for BUN). Two week treatment with CV-6504(HCI)
caused significant suppression of the plasma cholesterol and
BUN levels (99.1 10.1 mg/dl for cholesterol, P < 0.01, and
20.2 0.6 mg/dl for BUN; P < 0.05; Table 2).
Levels of MDA, 11-dehydro-TXB2 and LTs in plasma and
urine: Experiment 2
As shown in Figure 4, the level of plasma MDA and urinary
excretion of MDA were significantly higher in the PAN-treated
control rats (12.5 2.5 nmol/ml for plasma MDA and 19.0 5.0
nmol/lOO g/24 hr for urinary MDA) day 14 following PAN
injection than in normal rats (1.0 0.5 for plasma MDA and 4.2
0.1 nmol/100 g/24 hr for urinary MDA). In the rats given
CV-6504(HCI) (10 mg/kg, p.o.) for two weeks, these MDA
levels were significantly lower (6.1 1.5 nmollml for plasma
MDA and 7.6 0.5 nmolIlOO g/24 hr for urinary MDA excre-
tion) than those in the PAN-treated control rats. The levels of
1 1-dehydro-TXB2 in plasma and urine tended to be higher in the
PAN-treated control rats but not significantly so (plasma, 12
3 for normal rats and 44 18 pg/mI for PAN-control rats; urine,
598 140 for normal and 799 180 pg/l00 g!24 hr for
PAN-control rats), and the administration of CV-6504(HCI) for
14 days significantly decreased urinary 1 1-dehydro-TXB2 (plas-
ma, 25 8 pg/mI, urine, 280 80 pg/100 g/24 hr; P < 0.05 vs.
PAN-control rats). The levels of LTs in plasma and urine were
not higher in the PAN-treated control rats (plasma, 316 110
for normal rats and 338 55 pg/mI for PAN-control rats; urine,
1606 238 for normal rats and 1594 230 pg/l00 g/24 hr for
PAN-control rats).
Production of TXA2 and LTs in renal cortical slices and
MDA production and content in the renal cortical slices and
tissue: Experiment 2
As shown in Figures 1 and 5, 14 days after the injection of
PAN, the production of TXB2 and LTs from AA in renal
cortical slices was enhanced (0.17 0.03 ng/mg/30 mm for
TXB2 and 21.7 2.6 ng/mg/30 mm for LTs) as compared with
that in the slices from normal rats (0.01 0.01 ng/mg/30 mm for
TXB2 and 0.13 0.04 ng/mg/30 mm for LTs). In the cortical
slices from the rats treated with CV-6504(HCI) for two weeks,
TXB2 and LTs were not produced from AA (Fig. 5). The
production of MDA in the renal cortical slices from the PAN-
treated rats (0.24 0.07 nmollmg proteinl45 mm) was no higher
than that in the slices from normal rats (0.32 0.05 nmollmg
protein/45 mm). The content of MDA in the renal cortex in the
PAN-treated rats (0.58 0.03 nmoL/mg protein) was also no
higher than that in normal rats (0.50 0.06 nmolimg protein) 14
days after PAN injection. The production of MDA in the slices
and the content of MDA in renal cortex were not changed by
the administration of CV-6504(HCI) (data not shown).
Inhibitory effect of CV-6504(HC1) on the production of TXA2,
LTs and MDA in the renal cortical slices or renal glomeruli
in in vitro and ex vivo experiments (single administration):
Experiment 4
One hour after CV-6504(HCI) (10 mg/kg, p.o.) was adminis-
tered to the rats 14 days after PAN injection, the production of
TXB2 and LTs in renal cortical slices was inhibited by about
80% and about 60%, respectively (Fig. 6), and the production of
both eicosanoids was also markedly inhibited in renal glomeruli
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Table 2. Effect of two week CV-6504(HCI) administration on body weight, kidney weight, urine volume a
albumin, cholesterol, blood urea nitrogen (BUN) and creatinine in Experime
nd the concentrat
nt 2
ions of plasma
Urine Plasma Plasma
Body wt Kidney wt volume Plasma cholesterol
mi/IOU g albumin
g /24 hr g/dl
BUN creatinine
mg/dl
Normal 218 3 0.82 0.08 7.2 1.0 3.87 0.09 76.6 4.5 16.8 1.5 0.398 0.007
(5)
PAN rat 173 6 1.05 0.28 6.7 0.5 3.11 ØØ9 187.5 214b 26.6 2.2a 0.404 0.012
(10)
PAN rat 198 3 0.96 0.14 8.3 0.9 3.77 0.07' 99.1 10.1" 20.2 0.6c 0.401 0.021
CV-6504
10 mg/kg
(10)
Abbreviation is: PAN rat, puromycin aminonucleoside (100 mg/kg, i.p.)-treated rats. The number of animals used is indicated in parentheses.
Significance was by Student's t-test.
a P < 0.05, bp < 0.01 vs. normal rats
P < 0.05, "P < 0.01 vs. PAN rats
(Table 4). The production of MDA was though not inhibited.
However, when CV-6504(HCI) was added to the incubation
medium of renal cortical slices from rats 14 days after PAN
injection, it concentration-dependently inhibited the production
of TXB2 and LTs from exogenous AA with IC50 values of 4.8 x
10 M and 3.6 x i0 M, respectively, and also inhibited the
production of MDA with an IC50 value of 5.0 x iO M.
CV-6504(HCI) did not inhibit the production of 6-keto-PGF1 at
concentrations of 106 to l0— M (data not shown).
Antiproteinuric effect of the combined administration of CV-
4151, AA-861 and CV-3611: Experiment 5
In the rats 14 days after PAN injection, a single dose of
CV-4151 (a TXA2 synthetase inhibitor, 10mg/kg, p.o.), AA-861
(a 5-lipoxygenase inhibitor, 300 mg/kg, p.o.) or CV-3611 (a
radical scavenger, 50 mg/kg, p.o.) significantly inhibited the
production of TXB2, LTs and MDA, respectively, in renal
cortical slices (Fig. 7) (Experiment 4). The inhibition of the
production of TXA2 and LTs caused by CV-4l51 at 10 mg/kg
and AA-861 at 300 mg/kg was almost equal to that caused by
CV-6504(HCI). On the other hand, neither a single dose nor
chronic administration of CV-36l 1 at 50 mg/kg (p.o.) reduced
MDA levels in plasma or urine of PAN-treated rats (data not
shown). Any of these three drugs alone slightly reduced the
urinary protein. AA-861 or CV-3611 attenuated the proteinuria
only in one of three experiments at 50 mg/kg (p.o.) and 300
mg/kg (p.o.) for 14 days, respectively (data not shown). How-
ever, the combined administration of two drugs (AA-861 +
CV-4151 or AA-861 + CV-361 1) did so slightly but significantly.
The combination of all three drugs showed a clear antiprotein-
uric effect (Fig. 8).
Discussion
Although the levels of urinary and plasma I 1-dehydro-TXB2
(a stable metabolite of TXA2 which is not affected by blood
collection) and LTB4 were not higher in PAN-control rats and
the basal levels (without AA stimulation) of TXA2 and LTs
were not higher in renal cortical slices from PAN-control rats,
the present study has revealed that MDA content and renal
cortical production of TXA2 and LTs from AA are enhanced in
PAN-treated rats (Fig. 1). Since eicosanoids such as TXA2 and
Table 3. Histological findings in the kidneys of rats with puromycin
aminonucleoside-induced nephrosis: Effects of CV-6504(HCI) in
Experiment 2
The number of rats
CV-650
Normal (HCI)-treated
rats PAN rats
____
(N=10)
0 4
0 6
0 0
0 0
5
0
0
4
6
0
3
4
0
3
4
3
3
0
0
3
6
b
PAN rats(N = 10)
5
3
2
0
0
4
4
6
3
0
6
3
0
2
4
2
2
b
Interstitial tissue
Cell infiltration 2 0 7
1 5 3
b
Fibrosis 2 0 3
1 0 2 1
0 5 5 8
Five week old male Wistar rats were used. CV-6504(HCI) was
administered 1 hr before puromycin aminonucleotide (PAN) injection
and then administered daily for 13 days.
a The basis of the scores is described in Methods
"P < 0.05 and c P < 0.01 vs. normal rats; and "P < 0.05, P < 0.01
vs. PAN rats (non-parametric Mann-Whitney U test)
Glomerulus
PAS-positive
droplets
Tubules
Hyalin cast
Dilatation
Basophilic
alteration
Atrophy
Scorea
4
3
2
0
4
3
2
0
3
2
0
3
2
0
3
2
0
0
0
0
0
5
0
0
0
S
0
0
0
5
0
0
0
5
2
8d
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Fig. 3. Electron microscopy of a kidney from a rat 14 days after the injection of PAN (Experiment-2). A. PAN control rat, Fusion of foot processes
is evident. B. CV-6504(HCI)-treated rat. Fusion of foot processes is much less evident. Arrows show the foot processes. P: platelet (x 7500).
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Fig. 4. Plasma malondialdehyde (MDA) concentration and urinary
MDA excretion day 14 after PAN injection (Experiment 2). Abbrevia-
tions are: a, age-matched normal rats (N = 5); b, PAN control rats (N
= 10; c, CV-6504(HC1) (10 mg/kg, p.o. for 2 weeks)-treated rats (N =
10); *< 0.05, < 0.01 vs. PAN control rats (Dunnett's test)
LTs are known not to be stored, it is reasonable that the basal
level of these eicosanoids was not different between PAN-
control rats and normal rats. The local production of these
eicosanoids might be enhanced by some stimulation in PAN-
control rats. The chronic administration of CV-6504(HC1),
which inhibited the production of TXA2 and LTs (in vitro and
cx vivo) and MDA (in vitro), did remarkably attenuate the
**
5
01— I 0
a b c a b c
Fig. 5. The production of TXA2 and LTs in renal cortical slices
incubated with exogenous arachidonic acid (AA) 14 days after PAN
injection (Experiment 2). Renal cortical slices were incubated with AA
(final 20 M) for 30 mm at 37°C, TXB2 and LTs in the incubation
medium were measured by radioimmunoassay. Abbreviations are: a,
normal rats (N = 5); b, PAN rats (N = 7); c, CV-6504(HC1) (10 mg/kg,
p.o., for 2 weeks)-treated rats (N = 8); ** < 0.01 vs. normal rats and
CV-6504(HCI)-treated rats (Dunnett's test).
proteinuria. Even when CV-6504(HCI) was administered one
day after PAN injection, it attenuated the PAN-induced pro-
teinuria. Therefore, it is unlikely that CV-6504(HCI) affects the
:1) ,A
•1
Shibouta et a!: TXA2, LTs and radicals in PAN 927
delivery of PAN to the kidney or the uptake of PAN by the
kidney.
Although it has been reported that oxygen metabolites [1—51,
TXA2 [6, 7] and LTs [8—11] may be potent mediators for the
induction of proteinuria, there have been no reports demon-
strating simultaneous enhanced renal production of TXA2 and
LTs in PAN-treated rats. Moreover, this is the first report
showing the potent antiproteinuric effect of simultaneous inhi-
bition of lipid peroxidation and the production of TXA2 and
LTs. We have, however, been so far unable to determine the
precise mechanisms and the cell types responsible for the
acceleration of the lipid peroxidation and the production of
TXA2 and LTs.
Since MDA is the final peroxidation product of phospholip-
ids, an increase in the amount of MDA may indicate the
enhancement of lipid peroxidation. Although the level of
plasma MDA, urinary MDA excretion and MDA content in the
renal cortex was increased by day 7 after PAN administration,
the production of MDA by renal cortical slices was not en-
hanced in the PAN-treated rats. Furthermore, CV-361 1 (a
radical scavenger) did not attenuate the proteinuria and the
increased MDA in plasma and urine, while in vivo administra-
tion of CV-361 1 did reduce the production of MDA in renal
cortical slices. On the other hand, chronic in vivo administra-
tion of CV-6504(HCI) did not inhibit the production of MDA in
renal cortical slices, but the proteinuria was attenuated and
MDA levels in plasma and urine were lower than in PAN-
control rats. Therefore, it appears that the MDA detected in the
plasma, urine and renal cortex is different from that found in the
incubation medium of renal cortical slices. The increased MDA
noted in urine of PAN-control rats may be a non-specific result
of the presence of lipid-bearing proteins passively carried into
the urine through a leaky glomerular basement membrane.
Therefore, the reduction in the MDA concentration in urine by
chronic administration of CV-6504(HC1) would be secondary to
the reduction of the proteinuria. MDA in plasma may be
Table 4. Inhibitory effects of CV-6504(HC1) on the production of
thromboxane A2 (TXA2) and leukotrienes (LTs) in renal glomeruli of
rats with puromycin-induced nephrosis in Experiment 4
TXA2 LTs
pg/mg protein/30 mm ng/mg protein/30 mm
AAstimulateda AA-stimulated
Normal (3) 9.4 6.3' 0.04 0.02c
PAN rats (8) 184.7 55.7 22.40 4.20
PAN rats with 15.2 8.9k' 7.80
CV-6504(HC1) (8)
derived from various tissues, including kidneys, heart and liver,
damaged by PAN administration. Although the radical scaveng-
ing effect of CV-6504(HC1) in vivo or ex vivo was not observed
in the present experiments, inhibition of the MDA production
was observed when the drug was added in vitro to the incuba-
tion medium of renal cortical slices. Therefore, the radical
scavenging effect might be partially involved in the antipro-
teinuric effect of CV-6504(HC1).
Although Thakur, Walker and Shah reported that the pre-
dominant radical in PAN nephrosis is the OH radical [5], it is
unclear whether or not the generated MDA in plasma, urine and
cortical slices is the OH radical and whether or not CV-36l1
scavenges OH radicals.
The increase in renal MDA content might be due to an
increased renal uptake of plasma lipoprotein, as the increase in
renal MDA content was preceded by an increase in the plasma
cholesterol level (Table 1, Fig. lD).
As for LTs, Lefkowith, Morrison and Schreiner [8] reported
that no synthesis of LTs from exogenous AA occurs in the
glomeruli in normal rats. The amount of generated LTs in
cortical slices from normal rats was about 1/100 of that in those
from PAN-treated rats in the present experiments (Figs. lF, 5).
Although PAN-induced glomerular injury is known to be neu-
trophil-independent [37], there are extensive references to the
rather severe interstitial infiltration in PAN nephrosis first
described by Eddy and Michael [38], and to the glomerular
accumulation of macrophages, described by Schreiner, Cotran
and Unanue [37], and Diamond et a! [39], all of which note 5- to
10-fold increases in the infiltration of leukocytes in both the
glomerulus and interstitium and note increased production of
lipoxygenase products, uniquely produced by leukocytes, and
reactive oxygen species, also known to be produced by leuko-
cytes. In the present experiments, infiltration of inflammatory
cells was not observed in the glomeruli but was observed in the
interstitial cells in this model on day 14 (Table 3). Therefore,
these inflammatory cells may partially explain the cellular origin
of LTs. On the other hand, since the accumulation of platelets
was not observed, the resident renal cortical cells may be
responsible for the production of TXA2. It is uncertain whether
the activities of 5-lipoxygenase and TXA2 synthetase them-
selves are activated in the renal cortex of the PAN-treated rats.
The increase in BUN on day 1 might be related to this increase
in the production of TXA2 and LTs, since TXA2 and LTs are
10.0
(10)
0.5
0.4
0.3
0.2
0.1
5.01-
(10)
E
2
a ab
Fig. 6. Inhibition of the production of TXA2 and LTs in renal cortical
slices following a single dose of CV-6504(HC1) given to rats day 14 after
PAN injection (Experiment 4). *p < 0.05 vs. PAN control, CV-
6504(HC1); 10 mg/kg, p.o. The kidneys were removed 1 hour after the
administration of CV-6504(HCI). a, PAN-control; b, CV-6504(HCI).
0
b
0
Basal level (without AA): TXA2, 119.9 32.9 pg/mg/30 mm for PAN
rats (N = 16), 18.9 12.7 pg/mg/30 mm for normal rats (N = 3). LTs
were not detected in any group.
a AA; 20 jM arachidonic acid.b P < 0.05, C P < 0.01 vs. PAN rats
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Fig. 8. The effects of individual and combined administration of CV-
4151, AA-861 and CV-3611 for 14 days after PAN injection on the
proteinuria (Experiment-5). Abbreviations are: (a) normal rats without
PAN injection, (b) vehicle, (c) CV-4l51 (10 mg/kg, p.o.), (d) CV-3611
(50 mg/kg, p.o.), (e) AA-861 (300 mg/kg p.o.), (f) CV-4151 + CV-3611,(g) AA-861 + CV-3611, (h) AA-861 + CV-4151 and (i) AA-861 +
CV-4151 + CV-3611. The number of animals in each group was 7. P <
0.05, < 0.01 vs. vehicle (Dunnett's test). Urinary excretion of total
protein: (a) 11.0 1.4, (b) 159.8 11.8, (c) 145.6 5.9, (d) 141.2
13.2, (e) 116.2 7.3, (f) 144.1 11.8, (g) 89.7 5.9, (h) 113.2 8.8, (i)
85.3 5.9 mg/100 g124 hr.
known to cause a decrease in the glomerular filtration rate [6,
15, 16].
The antiproteinuric effect of CV-6504(HCI) was more potent
than that of the combined administration of CV-4151, AA-861
and CV-361 1. Therefore, the additional unknown action of
Fig. 7. The inhibitory effect of CV-4151, AA-861 and
CV-3611 on the production of TXA2, LTs and MDA,
respectively, in renal cortical slices from rats day 14PAN 10 50 after PAN injection (Experiment 4). P < 0.05, P <
mg/kg, p.o. 0.01, < 0.001 vs. PAN control.
CV-6504(HCI) may be attributed partially to the pathways
allegedly affected by CV-4151, AA-861 and CV-3611.
In summary, the present study demonstrated that in rats with
PAN-induced nephrosis, the ability of renal cortical slices and
glomeruli to produce TXA2 and LTs was enhanced, and MDA
content was transiently increased. CV-6504(HCI) showed a
very potent antiproteinuric effect, compared with a specific
inhibitor alone or with the combination of two inhibitors, in rats
with PAN-induced nephrosis. Although the detailed mecha-
nisms of the interactions among TXA2, LTs and free radicals
are unclear at present, all three of these mediators may be
involved in the initiation and the development of PAN-induced
nephrosis.
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